Last October, Cleveland's
ViewRay unveiled a research radiation therapy system to the medical device community. Now comes word that the Food and Drug Administration (FDA) has granted ViewRay clearance for its radiotherapy treatment planning and delivery software, a key element of the radiation therapy system.
This is a critical step toward FDA approval of the system, according to Gregory M. Ayers, M.D. and Ph.D., president and CEO of ViewRay. "It's exciting to see such progress with a product we believe will offer an advancement in radiation therapy," he says.
Combining MRI and radiotherapy delivery, the system provides a continuous MRI during radiation treatment. This helps doctors to see exactly where the radiation is going and to deliver precise treatment.
A recent $20 million Series C financing will help ViewRay in the final stages of development for commercial distribution. For now, the ViewRay system is only used in non-human settings.
A team of physicians and researchers leads the privately held medical device company. ViewRay is currently in growth mode and building its staff in quality assurance, software engineering, clinical science and sales.
Source: Gregory M. Ayers, ViewRay
Writer: Diane DiPiero
This story originally appeared in Fresh Water Cleveland.